A Gene Variant Makes Beta-Endorphin Bind Three Times Tighter to the Opioid Receptor — With Implications for Addiction

DNA was sequenced from 113 former heroin addicts in methadone maintenance treatment and 39 control individuals with no history of drug or alcohol abuse. Five SNPs were identified in the mu opioid receptor coding region. The A118G variant receptor was expressed in cell culture systems and tested for binding affinity with multiple opioid peptides and drugs, and for functional activity via G protein-coupled potassium channel activation assays.

This landmark study was one of the first to show that a common genetic variation could alter how the body responds to its own endorphin peptides. The finding has profound implications: if 10% of people have receptors that respond three times more strongly to beta-endorphin, this could influence their baseline pain sensitivity, reward processing, stress responses, and potentially their vulnerability to opioid addiction — all driven by a single nucleotide change.

This study sits at the intersection of genetics, peptide biology, and addiction medicine. It was foundational in the field of pharmacogenomics — the idea that genetic differences explain why people respond differently to drugs and their own neurotransmitters. The A118G variant has since become one of the most studied polymorphisms in addiction genetics. The finding that the effect is specific to beta-endorphin (not morphine or fentanyl) highlights how endogenous peptide signaling can be genetically tuned.

The study used a relatively small sample (152 individuals) and the heroin addict cohort may not be representative of the general population. While the binding and signaling differences are clear in vitro, translating these to real-world addiction risk requires population-level studies. The ethnic variation in allele frequency was noted but not fully characterized. Subsequent studies have debated the strength of the association between A118G and addiction risk.